SIDE-BY-SIDE COMPARISON

CompareInsitrovsAtomwise

Review features, pricing signals, strengths, and trade-offs before choosing.

Generated from current catalog profiles Catalog profile signals Use-case comparison
AI Drug Discovery & Molecule Design Software

Insitro

SF 8.2

ML drug discovery with proprietary biology data

Contact sales

Quick decision guide

Choose based on your workflow

Not enough differentiated product data yet to make a strong automatic pick.

Overview

How each tool is described

Insitro

Insitro is a machine learning drug discovery company that combines proprietary biological data generation with predictive modeling for drug targets. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.

For pharma partners on data-rich discovery programs, Insitro is worth a serious look thanks to full-stack ml plus wet-lab integration. The honest trade-off is that engages mainly via partnership not subscription. Pricing is sales-led and scoped per buyer rather than posted publicly. Buyers should still verify EHR or workflow fit, scope, and support before committing.

View full Insitro profile

Atomwise

Atomwise is an AI-powered drug discovery platform that helps pharmaceutical and biotechnology organisations identify potential small-molecule medicines using deep learning. Built for research teams rather than individual users, it combines virtual screening, structure-based modelling and biological data analysis to support early-stage drug discovery.


• Built for pharmaceutical and biotechnology organisations seeking to accelerate small-molecule drug discovery with AI.

• Uses AtomNet deep learning technology to identify potential drug targets, screen compounds and support structure-based drug design.

• Supports drug discovery across multiple therapeutic areas through research partnerships with pharmaceutical companies.

• Available through partnership agreements rather than self-service, with custom pricing and implementation tailored to each organisation.


Atomwise is best suited to pharmaceutical and biotechnology organisations investing in AI-assisted drug discovery, although its partnership-based model may be less suitable for smaller research teams looking for self-service software.

View full Atomwise profile

Side-by-side

Key differences

Criteria
AI Drug Discovery & Molecule Design SoftwareInsitro
AI Drug Discovery & Molecule Design SoftwareAtomwise
Best for
AI Drug Discovery & Molecule Design Software
AI Drug Discovery & Molecule Design Software
Score
8.2/10
7.9/10
Pricing
Contact sales
Contact sales
Category / audience
AI Healthcare & Medical Software › AI Drug Discovery & Molecule Design Software
AI Healthcare & Medical Software › AI Drug Discovery & Molecule Design Software

OVERLAP

Where Insitro and Atomwise are similar

Both tools cover similar catalog signals. The deciding factor is usually workflow fit, implementation needs, and ecosystem fit.

4 capabilities5 workflows

Shared capabilities

Capability overlap

  • Protein ModelingPredicts and designs protein structures
  • Knowledge GraphConnects biological and chemical knowledge sources
  • Virtual ScreeningScreens compound libraries against targets
  • Literature IntelligenceMines biomedical literature for relevant evidence

Shared workflows

Workflow overlap

  • Support protein engineering programsSupport protein design and engineering programs.
  • Mine literature for research signalsMine biomedical literature for research and target signals.
  • Run virtual screens against targetsRun virtual screening across large compound libraries.

Feature check

Side-by-side feature check

Feature
Insitro
Atomwise
Multi OmicsIntegrates genomic and other omics data sources
-
Lab IntegrationConnects discovery insights with wet-lab workflows
-
Target DiscoveryIdentifies potential drug targets using biological data
-
Molecule DesignGenerates and ranks potential small-molecule drug candidates
-
Protein ModelingPredicts and designs protein structures
Knowledge GraphConnects biological and chemical knowledge sources
8 capabilities compared.4 differentiating rows are shown first.

The trade-offs

Pros & cons of each tool

Trade-offs

Insitro

Pros
  • Full-stack data plus ML drug discovery
  • Proprietary human cell data generation depth
  • Validated through major pharma collaborations
Cons
  • Engages mainly through pharma partnerships
  • Not a buyer-facing software subscription
  • Drug success still depends on clinical work
Trade-offs

Atomwise

Pros
  • AtomNet-powered structure-based drug discovery
  • Partnerships across multiple therapeutic areas
  • Strong focus on small-molecule virtual screening
Cons
  • Available through partnerships rather than self-service
  • Drug candidates require further clinical development
  • Narrower focus than end-to-end drug discovery platforms

Final verdict

Best fit depends on your workflow

Catalog verdict · low confidence

Current catalog data shows meaningful overlap between Insitro and Atomwise. Use the signals below to decide based on workflow, ecosystem, pricing, and implementation fit.

Shared catalog overlap

Insitro and Atomwise share 9 catalog signals, so the decision should focus on fit rather than broad capability alone.

Differentiators available

Insitro has 3 visible decision signals and Atomwise has 3.

Score signal

Insitro has the higher SoftFinders Score in the current catalog data.

TRY THEM YOURSELF

See which one fits your workflow

Both tools have their strengths, the best way to decide is to spend a few minutes inside each.